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Abstract
 
Skin cancer incidence is highest in white-skinned people. Within this group, skin types I/II
(sun sensitive/tan poorly) are at greater risk than skin types III/IV (sun tolerant/tan well). Stud-
ies in mice demonstrate that ultraviolet radiation (UVR)-induced suppression of cell-mediated
immune function plays an important role in the development of skin cancer and induces a sus-
ceptibility to infectious disease. A similar role is suspected in humans, but we lack quantitative
human data to make risk assessments of ambient solar exposure on human health. This study
demonstrates that ambient levels of solar UVR, typically experienced within 1 h of exposure to
noonday summer sunlight, can suppress contact hypersensitivity (CHS) responses in healthy
white-skinned humans in vivo
 
 
 
(
 
n
 
 5 
 
93). There was a linear relationship between increase in
erythema and suppression of CHS (
 
P
 
 
 
, 
 
0.001), and a moderate sunburn (two minimal erythema
doses [2 MED]) was sufficient to suppress CHS in all volunteers by 93%. However, a single
suberythemal exposure of either 0.25 or 0.5 MED suppressed CHS responses by 50 and 80%,
respectively, in skin types I/II, whereas 1 MED only suppressed CHS by 40% in skin types III/
IV. The two- to threefold greater sensitivity of skin types I/II for a given level of sunburn may
play a role in their greater sensitivity to skin cancer.
Key words: human • immunosuppression • contact hypersensitivity • seasons • sunscreen
 
Introduction
 
Solar ultraviolet radiation (UVR; 
 
z
 
295–400 nm) is a major
environmental carcinogen and the principle cause of skin
cancer, the most common cancer worldwide. The inci-
dence of all types of skin cancer has increased steadily over
the past few decades, and this is widely attributed to changes
in lifestyle that have resulted in increased exposure to am-
bient UVR (1). Further increases in UVR exposure are ex-
pected as a result of stratospheric ozone depletion (2).
UVR exposure also results in sunburn (erythema), skin
aging, and immune suppression. The latter plays an impor-
tant role in the development of skin cancer in mice, and a
similar role is suspected in humans (3). Furthermore, a posi-
tive correlation between the incidence of non-Hodgkin’s
lymphoma and ambient UVR, along with an elevated risk of
non-Hodgkin’s lymphoma in skin cancer patients (4), sug-
gests a possible role for UVR in noncutaneous malignancies.
Exposure to UVR also increases the incidence and/or
severity of infections in mice challenged with bacterial,
fungal, viral, or parasitic agents (5) and therefore has impor-
tant implications for susceptibility to infectious diseases and
vaccine effectiveness in humans. UVR suppresses cell-medi-
ated immune (Th1) responses, leaving humoral (Th2) re-
sponses intact (6). Given that Th1 and Th2 responses are
mutually antagonistic, UVR may have the potential to sup-
press or exacerbate the pathogenesis of several immuno-
pathological conditions, including some hypersensitivity
states that are dominated by a Th1 (e.g., organ-specific auto-
immune disorders) or Th2 (e.g., atopic allergy) immune re-
sponse (7). The United Nations Environment Programme
has expressed concerns about the potential health effects
that may result from increased exposure to UVR (8) but states
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that there are currently no quantitative data on UVR-induced
immunosuppression in humans to make assessments of the
risks of ambient exposure on human health.
The aim of this study in white-skinned people was to
determine the UVR dose–response relationship for suppres-
sion of cell-mediated immune function in vivo using single
UVR exposures at levels typical of those that might be ex-
perienced in UK summer sunlight. We also investigated
the relationship between UVR-induced erythema and im-
munosuppression in different skin types to determine if
protection against erythema, e.g., by sunscreens, is indica-
tive of protection against immunosuppression. As it is well
established that different genetic backgrounds affect suscep-
tibility to skin cancer in humans, we also investigated
whether susceptibility to UVR-induced immunosuppres-
sion is skin type dependent.
 
Materials and Methods
 
Volunteers.
 
93 healthy, white-skinned Caucasian volunteers
(18–35 yr old) were recruited from staff at Guy’s and St. Thomas’
Hospitals, London. The study was approved by the local ethical
committee, and volunteers gave informed consent to participate.
Skin type was assessed by interview and erythema assessment. 93
volunteers completed the study; 62 volunteers were skin type I/II
(sun sensitive/tan poorly), 44 females and 18 males. The remain-
ing 31 volunteers were skin type III/IV (sun tolerant/tan readily),
23 females and 8 males. Exclusion criteria were medication other
than the oral contraceptive pill, previous exposure of buttock
skin (test site) to sunlamps or sunlight, a history of atopy, or pre-
vious exposure to the contact allergen 2,4-dinitrochlorobenzene
(DNCB; Sigma-Aldrich Co. Ltd.). Pregnant or lactating females
were also excluded.
 
UVR Source and Dosimetry.
 
Solar-simulated radiation (SSR)
was generated by a 1-kW xenon arc solar simulator (Oriel Corp.)
giving an even field of irradiance (290–400 nm) of 
 
z
 
15 mW/
cm
 
2
 
 on the skin surface when 11 cm from the source. Irradiance
was routinely determined with a wide band thermopile radiome-
ter (Medical Physics) calibrated against a DM150 double monochro-
mator Bentham spectroradiometer (Bentham Instruments, Ltd.).
The spectral output of the solar simulator, normalized at 320 nm,
compared with the solar spectrum of noon summer sunlight
(London, 51
 
8
 
 
 
N) has previously been reported (9).
 
Irradiation Protocol.
 
The minimal dose of SSR required to in-
duce a just visibly perceptible erythema at 24 h (minimal erythema
dose [MED]) was determined on the buttock skin of each volun-
teer by a geometric series of six exposure doses with increments
of 
 
Ö
 
2. Volunteers were randomly assigned to different SSR treat-
ment groups and received a single SSR exposure on a 5 
 
3
 
 5 cm
 
2
 
site on the buttock of 0, 0.25, 0.5, 1.0, 2.0, or 3.0 MED. Each
dose group contained eight skin type I/II and eight skin type
III/IV volunteers, except for 0.25 and 3 MED, which were not
given for skin types III/IV. Quantitative measurements of
erythema (arbitrary units) were made in triplicate both before and
24 h after SSR exposure using a reflectance meter (Diastron). For
each individual, the increase in erythema was calculated by sub-
tracting the mean background reading from adjacent nonirradi-
ated skin.
 
Sensitization.
 
Volunteers were sensitized on buttock skin
with DNCB 24 h after irradiation. This was via the irradiated site
using a petrolatum-backed 12-mm filter disk, soaked in 50 
 
m
 
l of
0.0625% DNCB in ethanol (31.2 
 
m
 
g/50 
 
m
 
l). The filter paper disc
was mounted inside a 12-mm aluminum Finn chamber (Biodiag-
nostics Ltd.) and taped in place for 48 h. Two control groups
(skin type I/II) were sensitized with ethanol only to determine
the nonspecific irritant effects of DNCB challenge. Sites were ei-
ther unirradiated (
 
n
 
 5 
 
8) or received a single 3 MED SSR expo-
sure (
 
n
 
 5 
 
6) 24 h before application of ethanol.
 
Elicitation of Contact Hypersensitivity Response.
 
3 wk after sen-
sitization, volunteers were challenged on the normally UVR-
protected upper inner arm. 8-mm filter paper discs were placed
in 8-mm Finn chambers and soaked with 20 
 
m
 
l of hapten solu-
tions of various strengths. Five patches were placed on the test
site; one was soaked in ethanol only, and four were soaked in in-
cremental doses of DNCB (3.125, 6.25, 12.5, and 25.0 
 
m
 
g/20 
 
m
 
l).
The elicitation sites were marked on the arm with a surgical skin
marker. The patch was taped in place for 48 h. At hour 48, the
patch was removed and the skin was allowed to recover for a pe-
riod of 1 h. 49 and 72 h after challenge, elicitation sites were
quantified as outlined below.
 
Quantification of Contact Hypersensitivity Responses.
 
Full details
have already been published (10). In brief, the dermal thickness of
each elicitation site was quantified using a high frequency 20
MHz ultrasound scanner (Quality Medical Instruments Ltd.). Ul-
trasound images of each site were recorded immediately before
and 49 and 72 h after challenge, because the time course for the
maximum elicitation of the contact hypersensitivity (CHS) response
varies from person to person. The time point at which the great-
est response was measured was used to calculate the percentage
increase in dermal thickness as follows:
The percentage increase in dermal thickness for each elicitation
site was plotted versus DNCB challenge dose (x-axis), and the
dose–response relationship was determined using linear regression
analysis. The CHS response of a given individual is represented
by the slope of the linear regression line. The steeper the slope,
the stronger the response.
 
Calculation of UVR-induced Immunosuppression.
 
The slope of the
elicitation response for each of the SSR-treated individuals was
then used in the formula below to calculate percentage suppres-
sion of CHS:
where IR 
 
5
 
 irradiated and UR 
 
5
 
 unirradiated.
 
Statistical Analyses.
 
Erythema was analyzed using multiple re-
gression analysis on the measured erythema response, and interac-
tion terms were used to allow for different responses by different
skin types while omitting the constant to force the lines through
zero. Immune response (CHS) was analyzed using interval regres-
sion on the log
 
10
 
 of the slope, taking zero values below 0.02
(slightly below the lowest real observed value). The multiple re-
gression models fitted were adjusted for seasonal differences. Ob-
servations were placed in five groups according to the month of
the year in which they were made: April/May, July/August, Octo-
ber, or December/January. Comparisons were made with June
(the month with the highest response). Standard multiple regres-
sion techniques were used to compare erythema or CHS responses
between these time periods and to make adjustments for skin types
and SSR dose. Data was analyzed, on an individual volunteer basis,
with Stata statistics/data analysis software (Stata Corp.). Robust SEs
were used to correct for nonnormality and unequal variances (11).
Dermal thickness at 48 or 72 h Dermal thickness at 0 h – ()
Dermal thickness at 0 h
-------------------------------------------------------------------------------------------------------------------------------------------- 100%. ´
1 Slope of elicitation response in IR subject 
Mean slope of elicitation response in UR group 
------------------------------------------------------------------------------------------------------------------- èø
æö – 100%, ´ 
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Results
 
UVR-induced Erythema.
 
Exposure to 2 or 3 MED of
SSR induced a vivid but nonblistering sunburn in all vol-
unteers regardless of skin type. Tanning (assessed at 7–14 d)
was not visually detectable in volunteers with skin type I,
but exposure to 2 and 3 MED induced a very light tan in
skin type II volunteers and a medium tan in volunteers with
skin types III and IV.
Exposure to UVR induced a dose-dependent increase in
erythema in all skin types (Fig. 1 a), but for every 1 J.cm
 
2
 
2
 
of SSR, the erythema response of skin types I/II was signif-
icantly greater than for skin types III/IV by 14.5 arbitrary
erythema units (
 
P
 
 
 
, 
 
0.0001; 95% CI 9.3–19.7). The mean
physical SSR dose required to induce a MED in skin types
I/II was about twofold lower than for skin types III/IV: 3.2
and 5.5 J.cm
 
2
 
2
 
, respectively (
 
P
 
 
 
, 
 
0.001).
When the erythema responses were expressed in terms of
biological dose (i.e., MED; Fig. 1 b), the two dose–response
curves were almost superimposable. However, skin types
I/II had a small but significantly greater erythema response to
each MED challenge (16.0 erythema units;
 
 P 
 
, 
 
0.004; 95%
CI 5.2–26.6) compared with skin types III/IV, but this was
below the visual detection limit (
 
z
 
50 erythema units).
 
CHS Responses.
 
Unirradiated volunteers: All unirradi-
ated volunteers, regardless of skin type, were successfully
sensitized and developed a dose-dependent CHS response
to all four incremental challenge doses of DNCB. Control
volunteers who were sensitized with ethanol alone, with or
without prior exposure to 3 MED SSR, did not develop a
CHS response to any of the four incremental challenge doses
of DNCB.
 
Skin Types I/II Are More Sensitive to UVR-induced Immu-
nosuppression than Skin Types III/IV.
 
The relationship be-
tween suppression of CHS and SSR exposure was assessed
using three different measures of exposure: (a) physical dose
(J.cm
 
2
 
2
 
) and biological dose expressed as (b) MED multi-
ples and (c) erythema units. However the data were ex-
pressed, exposure to SSR induced a dose-dependent suppres-
sion of CHS in both skin type groups. Skin types I/II were
5.3 times more sensitive (95% CI 2.9–9.6,
 
 P 
 
, 
 
0.001) than
types III/IV when the CHS responses were plotted against
SSR dose (Fig. 2). The use of biological indicators of SSR
exposure reduced this difference, but the CHS response of
skin type I/II was still significantly lower than that of skin
type III/IV (
 
P
 
 
 
, 
 
0.01) by a factor of 2.8 (95% CI 1.4–5.6)
throughout the MED dose range studied (data not shown).
To determine if this difference was due to the higher
erythema responses of skin type I/II per MED challenge, the
CHS responses were compared with dose expressed as
erythema units (assessed just before sensitization). Reanaly-
sis confirmed that the CHS responses of skin types I/II
were still significantly lower than skin types III/IV (
 
P 
 
, 
 
0.03)
by a factor of 2.2 (95% CI 1.07–4.6).
The percentage of immunosuppression was calculated
from the CHS data, as outlined in Materials and Methods,
to compare the dose–response curves for immunosuppres-
sion with erythema (Fig. 3). A moderate but vivid sunburn
(2 MED) completely suppressed CHS (93%) in all volun-
teers regardless of skin type, but skin types I/II were more
sensitive to suberythemal exposure.
 
Seasonal Variation.
 
As the study took 14 mo to com-
plete, we investigated the influence of season on CHS and
quantitative erythema responses. Both responses varied
with season, regardless of skin type or SSR challenge.
Erythema responses were highest in June and lower than
June levels from July to October by 15 erythema units (
 
P
 
 
 
,
 
0.01). CHS responses were also highest in June compared
with other months. Between July and October, CHS re-
sponses were 50% of those seen in June (CI 39–64%,
 
 P 
 
,
 
0.0001). Between December and April, CHS responses
were 29% of the June levels (CI 10–83%,
 
 P 
 
5 
 
0.021). Figs. 1
and 2 are adjusted for seasonal variation.
 
Discussion
 
Skin type, which is defined by an individual’s sensitivity
to sunburn and ability to tan, is a major risk factor for skin
cancer in white-skinned populations. Thus, Celtic popula-
tions (skin types I/II) are at greater risk than Mediterranean
populations (skin types III/IV) (1). In this study, we have
assessed whether sun-sensitive skin types I/II, who tan
poorly, and sun-tolerant skin types III/IV, who tan well,
might also differ in their susceptibility to UVR-induced
immunosuppression. To eliminate any possible confound-
ing effects of prior UVR exposure, we exposed our volunteers
Figure 1. SSR dose–response
curves for erythema. Skin types I/II
(s) were more sensitive to sunburn/
erythema than skin types III/IV (d).
The dose of UVR required to in-
duce a just visible reddening of the
skin (MED) was 3.2 and 5.5 J.cm22,
respectively (a). If the same data are
expressed as multiples of MED rather
than physical dose, the two dose–
response curves are comparable, but
skin types I/II still have a small (be-
low the visual threshold) but signifi-
cantly higher erythema response than
skin types III/IV (P , 0.002) (b). 
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to SSR on a small area of previously unexposed buttock
skin, where constitutive levels of pigmentation were similar.
Susceptibility to immunosuppression was clearly skin
type dependent. Skin types I/II were more readily suppressed
than skin types III/IV, requiring a fivefold lower physical
SSR dose than skin types III/IV to produce an equivalent
amount of immunosuppression (Fig. 2). A twofold differ-
ence was still observed when the two groups were chal-
lenged with an equivalent erythemally effective dose of
SSR. This sensitivity of skin types I/II to SSR-induced im-
munosuppression was striking. A single exposure to 0.25
MED suppressed CHS by 50%, and 0.5 MED suppressed
immune function by 80%. In comparison, skin types III/IV
were only suppressed with erythemal UVR exposures (1
MED and above; Fig. 3).
Release of soluble mediators from UVR-exposed skin,
in particular TNF-
 
a
 
 and IL-10, plays an important role in
the induction of immunosuppression in mice (3, 6). We
have recently shown that the in vivo release of TNF-
 
a
 
 and
IL-10 in human skin is significantly greater in skin types
I/II than skin types III/IV after the same physical dose of
UVR or an equivalent MED challenge (12). We propose
that this differential release of mediators may be the basis for
the difference in susceptibility to immunosuppression in the
two skin type groups. Given that UVR-induced immuno-
suppression plays an important role in the development of
skin cancers in mice (3), it is likely that the greater sensitivity
to UVR-induced immunosuppression in skin types I/II may
contribute to their increased skin cancer risk. However, we
must stress that despite a difference in sensitivity to immuno-
suppression, a vivid but nonblistering sunburn (2 MED) was
sufficient to suppress immune function in all skin types by
93%. Therefore, it is important that all white-skinned Cau-
casians take steps to reduce exposure to sunlight and avoid
sunburn to reduce their risk of skin cancer.
Previous studies in white-skinned people, using a more
aggressive irradiation protocol delivered over several days,
have suggested that only 40% (12/32) of the normal popu-
lation is susceptible to UVR-induced immunosuppression
(13). Similar results, with the same irradiation protocol, were
observed in sun-tolerant brown/black-skinned people,
suggesting no relationship between the erythemal response
and immunosuppression (14). To date, no immunological
or genetic basis for the UVR-resistant and UVR-suscepti-
ble human phenotypes has been found (15, 16). Similar
studies by the same group identified UVR-resistant and
-susceptible strains of mice (17), but this finding was refuted
by other workers, who showed that all mouse strains were
susceptible to UVR-induced immunosuppression when a
lower dose of hapten was used to sensitize the mice (18).
Other workers have also shown that the level of UVR-
induced immunosuppression is dependent on the dose of
sensitizer applied to the skin (19) and that there was less
suppression of CHS when high doses of sensitizer were
used. The dose of sensitizer used in our study was 64-fold
lower than that used by previous investigators (13, 14) and
is probably a more sensitive way of detecting UVR-induced
immunosuppression.
The ability of low to moderate doses of UVR to alter
the CHS response suggests a possible role for solar exposure
in the regulation of normal cutaneous immune function.
Not only did low-dose UVR suppress local CHS responses,
but our previous studies showed that 3 MED SSR sup-
pressed CHS responses by 93% (12/12 volunteers) when
sensitizer was applied to irradiated skin and also suppressed
CHS responses by the same amount (10/12 volunteers) when
sensitizer was applied at a distant site 24 h after irradiation
(10). The ability of UVR to suppress CHS responses sys-
temically suggested that our results may have been influ-
enced by variations of ambient solar exposure over the 14-mo
study period. We investigated this possibility and found that,
in contrast to what may have been predicted, CHS responses
were actually higher in the summer than in the winter, even
though in the UK daily ambient UVR is 
 
z
 
40-fold higher in
summer than in winter. Furthermore, a similar seasonal trend
was seen for erythema. The reasons for this seasonal variation
are unknown, but evidence is accumulating that seasonal in-
Figure 2. Skin types I/II are more susceptible to UVR-induced immu-
nosuppression than skin types III/IV. Analysis of individual (s, skin type
I/II; d, skin type III/IV) and mean (n, skin type I/II; m, skin type III/
IV) slopes for CHS response shows that SSR exposure induced a highly
significant dose-dependent suppression of cell-mediated immunity in all
skin types (P , 0.001). CHS responses of skin types I/II were 5.3-fold
lower than those of skin types III/IV throughout the dose range studied
(P , 0.001; 95% CI 2.9–9.6).
Figure 3. Sunburn is not a useful indicator of immunosuppression in
skin types I/II. Skin types I/II (s) were suppressed with doses of SSR
that were below the visual threshold for erythema (1 MED). In contrast,
skin types III/IV (d) were suppressed with erythemogenic doses of SSR.
All skin types were suppressed with a moderate sunburn (2 MED). 
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fluences on the neuroendocrine network play a role in sys-
temic modulation of immune responses and cytokine release
(20, 21). We stress, however, that our data clearly show that
the immunosuppressive effects of acute UVR exposure in an
experimental situation are dominant over any seasonal en-
hancement of immune function.
Our data show that equivalent erythema responses in dif-
ferent skin types result in different levels of immunosup-
pression. Consequently, the erythema response is not a use-
ful indicator of immunosuppression, especially in skin types
I/II, in which immunosuppression is seen with suberythe-
mal exposure. Sunscreens are widely advocated to reduce
the risk of skin cancer, but there have been concerns about
their ability to protect against immunosuppression (22).
Significant suppression of CHS by suberythemal exposure
in skin types I/II indicates that prevention of erythema by
sunscreens does not necessarily protect against immunosup-
pression. For example, a sunscreen of sun protection factor
(SPF) 10 reduces the UVR reaching the skin to 1/10th. 3
MED is readily achievable by skin types I/II in the UK af-
ter 1–2-h exposure to summer sunlight, allowing an SPF 10
user to receive 0.3 MED (3 MED/10). Under these condi-
tions, there will be protection against erythema but not im-
munosuppression, but shorter exposure times might result in
protection from both endpoints. The real impact of UVR
exposure may be greater than predicted by our studies. We
irradiated a small area of skin, but mouse studies indicate that
a given UVR dose per unit area is more immunosuppressive
when larger areas of skin are irradiated (19), such as with
sunbathing. These data indicate the importance of public
health campaigns stressing that sunscreens should be used as a
part of an overall strategy to reduce UVR exposure, which
includes wearing protective clothing and the avoidance of
sun around noon, when levels of UVR are highest.
The study of the immunosuppressive effects of UVR has
so far focused on skin cancer and infectious disease. Our study
also implies that vaccinations would be less effective if given
in the summer or after holidays in the sun. However, as
vaccines are usually given intradermally rather than epicu-
taneously, as was the antigen used in our study, further work
is needed to clarify this point. Finally, given the potency of
UVR to modulate immune function in humans, our data
suggest that the effects of UVR on allergic and autoimmune
diseases should be explored. Further work is also needed to
extend our knowledge about the possible effects of UVR-
induced immunosuppression and susceptibility of people of
different ethnic backgrounds to these diseases.
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